Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.

Employees

122

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	HKD 2.790	-1.24%	392,000
29/10/26	HKD 2.825	-0.53%	282,000
28/10/26	HKD 2.840	+2.34%	1,049,500
27/10/26	HKD 2.775	-5.61%	1,096,500
26/10/26	HKD 2.940	+1.91%	338,000

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.367CNY

Average target price

4.150CNY

Spread / Average Target

+75.33%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Antengene Corporation Limited

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Antengene Corporation Limited

Company calendar

Market Closed - Hong Kong S.E. 07:08:08 30/10/26 pm AEDT			5-day change	1st Jan Change
2.790 ^HKD	-1.24%		-3.29%	-26.39%

26/10	Antengene Corporation Limited Presents Latest Clinical Results For ATG-022 And ATG-037 At ESMO 2026	CI
09/10	Antengene Corporation Limited Announces Presentation Of Latest Preclinical Results Of ATG-207 At ACR 2026	CI

Market Cap	1.63B 1.92B 244M 219M 201M 183M 341M 23.22B 348M 2.4B 964M 12.21B 918M 898M 38.51B	P/E 2026 *	4.47x	P/E 2027 *	-18.2x
Enterprise Value	1.63B 1.92B 244M 219M 201M 183M 341M 23.22B 348M 2.4B 964M 12.21B 918M 898M 38.51B	EV / Sales 2026 *	1.96x	EV / Sales 2027 *	4.82x
Free-Float	62.79%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	6996	Delayed
Tradegate	722	Real-time
Börse Stuttgart	722	Delayed
Deutsche Boerse AG	722	Delayed

26/10	Antengene Corporation Limited Presents Latest Clinical Results For ATG-022 And ATG-037 At ESMO 2026	CI
09/10	Antengene Corporation Limited Announces Presentation Of Latest Preclinical Results Of ATG-207 At ACR 2026	CI
21/09	Antengene Corporation Limited Doses First Patient in Pivotal Phase III CLINCH-3 Study of ATG-022	CI
25/08	Antengene Corporation Limited Receives HREC Approval In Australia For Phase I ATTRACT Study Of ATG-201 In B Cell-Related Autoimmune Diseases	CI
25/08	Antengene's Autoimmune Disease Drug Candidate Approved for Phase I Trial in Australia	MT
21/08	Antengene Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
20/08	Antengene Presents Key R&D Highlights Including Atg-022 Clinical Data, Antengager and Trigager Tce Platforms, and Atg-207 Bifunctional Fusion Protein	CI
31/07	Antengene's CFO Steps Down; Chief Business Officer Named	MT
31/07	Antengene Corporation Limited Announces Management Changes, Effective August 1, 2026	CI
31/07	Antengene Corporation Limited Announces Resignation of Donald Andrew Lung as Chief Financial Officer, Effective August 1, 2026	CI
28/07	Antengene Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026	CI
13/07	Antengene Receives $60 Million Milestone in UCB Licensing Deal	MT
10/07	Soochow Securities Starts Antengene at Buy With HK$10.60 Price Target	MT

Antengene Corporation Limited Stock

Stocks

6996

KYG039571008

Biotechnology & Medical Research

Valuation: Antengene Corporation Limited

Chart: Antengene Corporation Limited

Latest news: Antengene Corporation Limited

Analysts' recommendations: Antengene Corporation Limited

Press Releases: Antengene Corporation Limited

Quotes and Performance

Price Extremes

Managers and Directors: Antengene Corporation Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

26/10	Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026	PR
09/10	Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026	PR
03/10	Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026	PR
21/09	Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022	PR
14/09	Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy	PR

1 day	-1.24%
1 week	-3.29%
Current month	-19.36%
1 month	-19.36%
3 months	-27.91%
6 months	-44.53%
Current year	-26.39%

1 week	2.7	3.02
1 month	2.7	3.54
Current year	2.7	6.28
1 year	2.7	6.28
3 years	0.5	8.16
5 years	0.5	13.06
10 years	0.5	22.5

Manager	Title	Age	Since
Jian Ming Mei CEO	Chief Executive Officer	60	28/08/2018
Bing Hou CTO	Chief Tech/Sci/R&D Officer	42	20/05/2026
Godfrey Guo CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jian Ming Mei CHM	Chairman	60	28/08/2018
Jing Qian BRD	Director/Board Member	51	09/11/2020
Rafael Fonseca BRD	Director/Board Member	59	14/04/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/9/26	Jing Qian	Other	Director	200,000	0.0294%
10/9/26	Bing Hou	Other		2,000,000	0.2944%
10/9/26	Rafael Fonseca	Other	Director	200,000	0.0294%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANTENGENE CORPORATION LIMITED	-1.24%	-3.29%	-43.41%	+91.10%	244M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+46.31%	+56.99%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.92%	+84.55%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+15.37%	+106.81%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+50.90%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+20.15%	+98.45%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+224.97%	+942.56%	41B
GENMAB A/S	+3.27%	+47.96%	+112.67%	+96.48%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.89%	+47.15%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-42.03%	+373.03%	24.7B
Average	+0.18%	+6.46%	+38.73%	+194.80%	39.46B
Weighted average by Cap.	+0.18%	+5.44%	+48.44%	+186.07%

	2026 *	2027 *
Net sales	830M 979M 125M 112M 103M 93.12M 174M 11.85B 177M 1.23B 492M 6.23B 468M 458M 19.65B	338M 398M 50.74M 45.44M 41.8M 37.87M 70.8M 4.82B 72.12M 498M 200M 2.53B 190M 186M 7.99B
Net income	333M 393M 50.07M 44.84M 41.25M 37.37M 69.86M 4.75B 71.17M 492M 197M 2.5B 188M 184M 7.89B	-84.79M -99.94M -12.74M -11.41M -10.49M -9.51M -17.77M -1.21B -18.11M -125M -50.24M -636M -47.81M -46.79M -2.01B
Net Debt	-	-